文献速递肿瘤 PET/CT放射性药物与辐射防护

[18F]FDG PET/MRI 实体瘤摄取的重测重复性:基于 QIBA 方案的前瞻性多中心研究

Test-Retest Repeatability of [18F]FDG Uptake by Solid Tumors on PET/MRI: A Prospective, Multicenter Study Using the QIBA Protocol.
PubMed 文献 · J Nucl Med · 2026-10-15

该前瞻性多中心研究评估了 [18F]FDG PET/MRI 在多种癌症类型中摄取指标的重测重复性。在两家机构使用不同 PET/MRI 扫描仪,按 QIBA 规范于 1–9 天内进行两次研究性 PET/MRI。结果显示 SUVmax 的 wCV 在 site 1 为 12.3%、site 2 为 9.5%,与 QIBA 对 [18F]FDG PET/CT 的 10%–12% 基准相似;隔次 μ-map 变异对重复性负面影响极小。

要点

  • SUVmax 的 wCV 在两中心分别为 12.3% 和 9.5%,与 QIBA PET/CT 基准 10%–12% 相似。
  • SUVpeak 的 wCV 分别为 9.6% 和 8.8%,略优于 SUVmax。
  • 隔次 μ-map 变异对重复性负面影响极小,替代 μ-map 后 SUVmax wCV 降至 10.1%。

核心结论

  • 高代谢病灶 SUVmax 在 [18F]FDG PET/MRI 上的重测重复性与 QIBA 对 [18F]FDG PET/CT 的 wCV 基准 10%–12% 相似。
  • 隔次 μ-map 变异对重复性负面影响极小。

研究设计与样本

  • 前瞻性多中心研究,涉及 2 家机构、使用不同 PET/MRI 扫描仪。
  • 受试者在 1–9 天内完成 2 次研究性 [18F]FDG PET/MRI(测试与重测),遵循 QIBA 规范。
  • 入组要求至少 1 个可测量病灶(长轴 ≥ 2 cm,已知或预期 SUVmax ≥ 4.0)且无活跃肿瘤治疗。
  • site 1 分析 10 例受试者共 11 个可测量病灶;site 2 分析 11 例受试者共 30 个可测量病灶。

主要发现

  • site 1 的 SUVmax 和 SUVpeak 的 wCV 分别为 12.3% 和 9.6%。
  • site 2 的 SUVmax 和 SUVpeak 的 wCV 分别为 9.5% 和 8.8%。
  • site 1 用重测 μ-map 重复测试 PET 的衰减校正后,SUVmax 的 wCV 降至 10.1%,SUVpeak 降至 9.1%。
  • site 1 的 11 个病灶中有 8 个在 μ-map 替代后测试-重测变化小于 5%,未见明显隔次 μ-map 差异或伪影。

关键数值与推荐

  • 可测量病灶定义:长轴 ≥ 2 cm,已知或预期 SUVmax ≥ 4.0。
  • 两次 PET/MRI 间隔 1–9 天,遵循 QIBA 规范。
  • QIBA 对 [18F]FDG PET/CT 的 wCV 基准为 10%–12%。

临床怎么用

  • 在 [18F]FDG PET/MRI 用于肿瘤疗效评估时,SUVmax 变化需超过约 10%–12% 的重复性范围才可能反映真实生物学改变。
  • 隔次 μ-map 变异对重复性影响小,临床解读 SUV 变化时不必过度顾虑 μ-map 差异。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Prior oncologic PET/MRI repeatability studies have been limited by single-center designs, small cohorts, or select patient populations. Our primary aim was to estimate the test-retest repeatability of uptake metrics on [18F]FDG PET/MRI studies across a variety of cancer types. A secondary aim was to assess the impact of intersession μ-map variability on repeatability. Methods: In this prospective study involving 2 institutions with different PET/MRI scanners, subjects completing standard-of-care [18F]FDG PET/CT or MRI examinations were recruited to undergo 2 research [18F]FDG PET/MRIs (i.e., test and retest) within a 1-9 d period per Quantitative Imaging Biomarker Alliance specifications. Enrollment required at least 1 measurable lesion (long axis ≥ 2 cm, known or expected SUVmax ≥ 4.0) and no active oncologic therapy. SUVmax and SUVpeak were extracted from measurable lesions (1-5 per subject). At site 1, attenuation-coefficient maps (i.e., μ-maps) were inspected for substantial differences across sessions. Additionally, at site 1, the retest μ-map was coregistered to the test μ-map, and the PET attenuation-correction process was repeated for the test session based on the retest μ-map. Intersession repeatability was assessed via Bland-Altman plots, and within-subject coefficients of variation (wCVs) were calculated. Results: At site 1, 10 subjects with 11 measurable lesions were analyzed, and the wCVs for SUVmax and SUVpeak were 12.3% and 9.6%, respectively. At site 2, 11 subjects with 30 measurable lesions were analyzed, and the wCVs for SUVmax and SUVpeak were 9.5% and 8.8%, respectively. At site 1, repeating attenuation correction of the test PET data with the retest μ-map slightly improved repeatability, reducing the wCV to 10.1% for SUVmax and to 9.1% for SUVpeak For 8 of 11 lesions at site 1, the μ-map substitution altered the test-retest change by less than 5%, with no appreciable intersession μ-map differences or artifacts. Conclusion: The test-retest repeatability of SUVmax among hypermetabolic lesions on [18F]FDG PET/MRI, using data from 2 scanner models, was similar to the Quantitative Imaging Biomarker Alliance's wCV benchmark of 10%-12% for [18F]FDG PET/CT. Intersession μ-map variations had minimal negative impact on repeatability.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Fraum TJ, Calderara G, An H, et al. Test-Retest Repeatability of [18F]FDG Uptake by Solid Tumors on PET/MRI: A Prospective, Multicenter Study Using the QIBA Protocol. J Nucl Med. 2026. PMID: 42880961. doi:10.2967/jnumed.126.272891

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。